Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Endometrial Carcinoma | Unmet Need | Advanced or Recurrent Endometrial Carcinoma | US/EU | 2022

Login to access report north_east
Contact sales account_box

Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of advanced or recurrent endometrial carcinoma, for which chemotherapy and hormonal therapy used to be the standard of care. Nevertheless, treatment options are limited in later lines of therapy and there remains a pressing need for more-effective treatments in the advanced or recurrent setting. We assess how current therapies perform on key drug attributes and measure the impact of drug attributes on physicians’ prescribing behavior for advanced or recurrent endometrial carcinoma. We also identify potential hidden opportunities emerging therapies could capitalize upon.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals in medical oncologists’ prescribing decisions in advanced or recurrent endometrial carcinoma? What are the hidden opportunities that developers could leverage?
  • How do key current therapies, such as immune checkpoint inhibitors, perform on key clinical attributes for this patient population?
  • What are the greatest unmet needs and most attractive opportunities for advanced or recurrent endometrial carcinoma?
  • What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in June 2022

Key companies: Merck & Co., Eisai, GlaxoSmithKline

Key drugs: Keytruda, Lenvima, Jemperli

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
north_east
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east